INVO Bioscience, a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, will exhibit their novel device at the American Society for Reproductive Medicine 2016 Scientific Congress.
INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, will exhibit their novel device at the American Society for Reproductive Medicine (ASRM) 2016 Scientific Congress, which will take place October 15-19 at the Salt Palace Convention Center, Salt Lake City, Utah, USA.
Katie Karloff, Chief Executive Officer of INVO Bioscience, commented, “INVO Bioscience is thrilled to be exhibiting for the first time at the ASRM Scientific Congress. We look forward to showcasing our novel INVO Solution which has disrupted the IVF industry by providing individuals struggling with infertility the opportunity to have access to a new state-of-the-art technology. Please come by our booth (#2000) and say hello. We look forward to seeing our current partners and physicians as well as forming new relationships with those wanting to offer their patients an affordable and more natural alternative to IVF or IUI.”
A SIMPLER WAY TO LIFE
The INVOcell is the first FDA cleared Intravaginal Culture (IVC) device, and is a small polystyrene capsule used for egg fertilization and embryo development using vaginal incubation. In this technique, the woman’s body is used as the natural incubator, laboratory incubators are only used to pre-warm media and disposable materials needed for the INVO Procedure. The advantage being the INVOcell utilizes the women’s vagina as the main source of incubation. Couples participating in this treatment feel more directly involved, and more in control of the destiny of the embryo.
Get the Facts about the INVO Solution at http://invobioscience.com/about-us/faq/.
INVO SOLUTION ADVANTAGES
For many struggling with infertility, access to treatment is often not possible. Financial challenges, limited availability of specialized medical care, religious, social and cultural roadblocks can prevent these hopeful parents from realizing their dream to have a baby.
With the INVO Solution, more and more patients can now receive safe, effective and affordable infertility treatment. To find a provider offering the INVO Solution please check our Partner Clinic Locations list or call (978) 878.9505 x503 or email us at email@example.com.
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, MA, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company’s lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman’s vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Kathleen Karloff, CEOINVO Bioscience, Inc.978-878-9505 ext. 504
Logo – http://photos.prnewswire.com/prnh/20160418/356831LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/invo-bioscience-to-exhibit-at-the-2016-american-society-for-reproductive-medicine-asrm-scientific-congress–booth-2000-300344937.html
SOURCE INVO Bioscience, Inc.